Vasoconstrictive properties of the 5HT1B/1D agonists:: response to Dahlof and Mathew

被引：0

作者：

Goldstein, D ^{[1
]}

机构：

[1] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA

来源：

CEPHALALGIA | 1999年 / 19卷 / 05期

关键词：

D O I：

10.1177/033310249901900503

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

收藏

页码：536 / 536

页数：1

相关论文

共 9 条

[1] Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan
Dahlof, CGH
Falk, L
Risenfors, M
Lewis, CP
[J]. CEPHALALGIA, 1998, 18 (08) : 546 - 551
[2] Cardiovascular safety of 5HT1B/1D agonists -: Is there a cause for concern?
Dahlof, CGH
Mathew, N
[J]. CEPHALALGIA, 1998, 18 (08) : 539 - 545
[3] MACINTYRE PD, 1992, BRIT J CLIN PHARMACO, V34, P541
[4] EFFECT OF SUBCUTANEOUS SUMATRIPTAN, A SELECTIVE 5HT1 AGONIST, ON THE SYSTEMIC, PULMONARY, AND CORONARY CIRCULATION
MACINTYRE, PD
BHARGAVA, B
HOGG, KJ
GEMMILL, JD
HILLIS, WS
[J]. CIRCULATION, 1993, 87 (02) : 401 - 405
[5] The reporting sensitivities of two passive surveillance systems for vaccine adverse events
Rosenthal, S
Chen, R
[J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1995, 85 (12) : 1706 - 1709
[6] SWAN L, 1997, CEPHALALGIA, V17, P428
[7] *US FDA, 1997, SUMM BAS APPR ZOLM
[8] *US FDA, 1998, SUMM BAS APPR NAR ND
[9] *US FDA, FREED INF SUM ADV EV